共 90 条
[1]
Tateishi R(2017)Global prevalence and genotype distribution of hepatitis c virus infection in 2015: a modelling study Lancet GastroenterolHepatol 2 161-176
[2]
Uchino K(2019)A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update J Gastroenterol 54 367-376
[3]
Fujiwara N(1997)Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann Intern Med 127 875-881
[4]
Marcellin P(1997)Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C Hepatology 26 780-785
[5]
Boyer N(2000)Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 132 517-524
[6]
Gervais A(1999)Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1124-1130
[7]
Shiffman ML(1998)Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 94-99
[8]
Hofmann CM(1999)Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy Ann Intern Med 131 174-181
[9]
Thompson EB(1998)Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C Hepatology 27 1394-1402
[10]
Shiratori Y(2013)Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study J Hepatol 58 495-501